drugset
drugset / Trial / NCT04435652

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

NCT04435652 ↗

Phase 2/3 Unknown 492 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.

Timeline

Start
2020-07-01
Primary completion
2022-04-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous
Subject QL1604 Monoclonal antibody 3 mg/kg Intravenous

Indications

gastroesophageal adenocarcinoma